Literature DB >> 15827754

The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro.

Tudor Bîrsan1, Camille Dambrin, Derrick G Freitag, Randall W Yatscoff, Randall E Morris.   

Abstract

ISA247 is a novel cyclosporine analog. In this study we compare, in vitro, the effects of ISA247 on immune function with those of cyclosporine. Whole blood from cynomolgus monkeys (n = 5) was incubated with different concentrations of ISA247 or cyclosporine and stimulated with different mitogens in culture medium. Lymphocyte proliferation was assessed by [3H]-TdR incorporation assay and by flow cytometry. Flow cytometry was also used to assess production of intracellular cytokines by T cells and expression of T cell activation surface antigens. The concentration of drug necessary to attain 50% of the maximum effect (EC50) was subsequently calculated. EC50 values for ISA247 were lower than for cyclosporine, and the differences were statistically significant for lymphocyte proliferation, T cell cytokine production, and expression of all T cell activation surface antigens but one. We conclude that ISA247 suppresses diverse immune functions more potently than cyclosporine in vitro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827754     DOI: 10.1007/s00147-004-0799-z

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  12 in total

Review 1.  Emerging drugs for uveitis.

Authors:  Theresa Larson; Robert B Nussenblatt; H Nida Sen
Journal:  Expert Opin Emerg Drugs       Date:  2011-01-06       Impact factor: 4.191

2.  The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture.

Authors:  Natacha S Ogando; Erik Metscher; Dirk Jan A R Moes; Eline J Arends; Ali Tas; Jennifer Cross; Eric J Snijder; Y K Onno Teng; Aiko P J de Vries; Martijn J van Hemert
Journal:  Transpl Int       Date:  2022-06-24       Impact factor: 3.842

3.  LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells.

Authors:  Matthew A Cunningham; Bobbie Ann Austin; Zhuqing Li; Baoying Liu; Steven Yeh; Chi-Chao Chan; Eddy Anglade; Poonam Velagaleti; Robert B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-15       Impact factor: 4.799

4.  Investigating the Release of a Hydrophobic Peptide from Matrices of Biodegradable Polymers: An Integrated Method Approach.

Authors:  Anna V Gubskaya; I John Khan; Loreto M Valenzuela; Yuriy V Lisnyak; Joachim Kohn
Journal:  Polymer (Guildf)       Date:  2013-07-08       Impact factor: 4.430

5.  Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin).

Authors:  Andreas Kuglstatter; Francis Mueller; Eric Kusznir; Bernard Gsell; Martine Stihle; Ralf Thoma; Joerg Benz; Launa Aspeslet; Derrick Freitag; Michael Hennig
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-01-15

6.  Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.

Authors:  Martin Roesel; Christoph Tappeiner; Arnd Heiligenhaus; Carsten Heinz
Journal:  Clin Ophthalmol       Date:  2011-09-13

7.  Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis.

Authors:  Manjula Karpurapu; Yong Gyu Lee; Ziqing Qian; Jin Wen; Megan N Ballinger; Luiza Rusu; Sangwoon Chung; Jing Deng; Feng Qian; Brenda F Reader; Teja Srinivas Nirujogi; Gye Young Park; Dehua Pei; John W Christman
Journal:  Oncotarget       Date:  2018-01-25

8.  Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

Authors:  Matthias Sieber; Ria Baumgrass
Journal:  Cell Commun Signal       Date:  2009-10-27       Impact factor: 5.712

Review 9.  Calcineurin inhibitors: a double-edged sword.

Authors:  Adaku C Ume; Tara-Yesomi Wenegieme; Clintoria R Williams
Journal:  Am J Physiol Renal Physiol       Date:  2020-11-23

10.  Voclosporin as a treatment for noninfectious uveitis.

Authors:  Clyde Schultz
Journal:  Ophthalmol Eye Dis       Date:  2013-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.